文 | 《BUG》栏目 张奥 老牌国货被检出有害物质？ 日前，第三方测评机构对 9 款女性私处护理贴（俗称雪莲贴）检测发现，其均包含重金属 物质。其中，有一产品出自妇炎洁。 从检测结果来看，妇炎洁雪莲贴铅含量为 1.7mg/kg ，砷含量为 0.66mg/kg ，两者均超 出行业标准两倍以上。同时，其还检测出呋喃香豆素， 3 种禁用物质含量超标。 截至发稿前，在妇炎洁官方旗舰店相关产品仍在售。业内人士透露，此类雪莲贴利润率超 1000% ，商家精准抓住女性对妇科问题"羞于启齿"的心理，以"草本排毒""调理保养" 为 噱头抬高身价。 对于"产品被检出金属含量超标"，妇炎洁官方客服表示："会第一时间进行核查。（雪莲 贴）产品严格按照相关要求生产，检验合格后上市，都是没有副作用的。" 妇炎洁雪莲贴 近日，第三方测评机构"老爸评测"对电商平台热销的 9 款女性私处护理贴（俗称雪莲贴） 进行检测发现，此类产品暗藏健康隐患。尤其重金属检测环节，所有送检产品均检出铅、砷 等重金属，且无一能达到其包装上声称执行的雪莲贴行标限量标准。 值得注意的是，通过人工尿液模拟实验发现，产品夹层中的棕色粉末会随分泌物反渗至皮 肤。进一步检 ...

（文章来源：证券日报） 证券日报网讯 2月13日，仁和药业在互动平台回答投资者提问时表示，截至2026年1月30日，股东人数 为9.6万户左右。 ...

Core Viewpoint - Renhe Pharmaceutical (000650) has undergone a change in its board secretary and has responded to potential restructuring matters while diversifying into smart hardware, adjusting its fundraising projects, and facing ongoing performance pressure, necessitating attention to policy compliance dynamics [1] Group 1: Executive Changes - On February 9, 2026, the company announced that board secretary Chen Guofeng resigned for personal reasons, with Jiang Feng succeeding him. This personnel change has been completed without affecting normal operations [2] Group 2: Recent Events - In an investor interaction on February 2, 2026, the company stated that any significant restructuring plans would be announced in strict accordance with regulations, indicating that investors should pay attention to potential future disclosures [3] Group 3: Business Progress - In December 2025, the company announced its entry into the AI smart wearable sector with the launch of ULOOK AI glasses, which is expected to drive new business growth [4] Group 4: Project Developments - In December 2025, the company announced adjustments to its female health product production line, terminating the digital health product line and reallocating remaining fundraising to supplement working capital, reflecting a strategic contraction [5] Group 5: Performance Overview - For the first three quarters of 2025, the company reported a 10.07% year-on-year decline in operating revenue and an 8.79% year-on-year decline in net profit attributable to shareholders. Investors should monitor whether future annual reports show improvement [6] Group 6: Policy Regulation - On January 29, 2026, the company indicated that the new requirements of the "Special Regulations on the Registration of Traditional Chinese Medicine" have not significantly impacted the operation of traditional Chinese medicine products, but ongoing attention to regulatory implementation is necessary [7]

Core Viewpoint - The appointment of Mr. Jiang Feng as the Secretary of the Board is a normal personnel arrangement aimed at ensuring continuity and compliance in the company's board operations [1][2] Group 1: Appointment Details - The 10th Board of Directors of Renhe Pharmaceutical Co., Ltd. held its sixth temporary meeting on February 9, 2026, where the appointment of Mr. Jiang Feng as the Secretary of the Board was approved [1] - The meeting was conducted via communication means, with all 9 directors present, and was chaired by Chairman Yang Xiao [1] - Mr. Jiang Feng's qualifications have been reviewed and approved by the Shenzhen Stock Exchange, and he has previously held various positions within the company [1] Group 2: Background of the New Secretary - Mr. Jiang Feng, born in October 1976, holds a bachelor's degree and an EMBA [1] - His career history is closely linked to the Renhe system, having served in multiple roles including Deputy Director of the Chairman's Office and Secretary of the Board [1] - He currently serves as a director of the company and does not hold any shares in the company, nor does he have any relationships with major shareholders or other board members [1] Group 3: Implications of the Appointment - The new Secretary's familiarity with the company's business and capital market operations is expected to enhance the continuity and standardization of the board's work [2] - Investors can contact the new Secretary through the company's published office phone, fax, email, and address [2]

Core Viewpoint - Renhe Pharmaceutical announced the resignation of its board secretary, Chen Guofeng, due to personal reasons, effective immediately upon delivery of the resignation report [2] Group 1 - Chen Guofeng's original term as board secretary was set to last until May 26, 2028, and he did not hold any shares in the company [2] - The board of directors approved the appointment of Jiang Feng as the new board secretary, with a term aligned with the current board [2]

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced the resignation of its board secretary, Chen Guofeng, due to personal reasons, effective immediately upon delivery of his resignation report to the board [1] Group 1: Resignation Details - Chen Guofeng's original term was set to expire on May 26, 2028, and he did not hold any shares in the company [1] - Following his resignation, Chen Guofeng will no longer hold any position within the company [1] Group 2: Appointment of New Secretary - To ensure the normal operation of the board, the company’s chairman nominated Jiang Feng as the new board secretary [1] - The appointment was approved during the sixth temporary meeting of the tenth board, with Jiang Feng's term aligning with that of the current board [1] - Jiang Feng possesses the necessary professional knowledge and skills, having obtained the Board Secretary Qualification Certificate issued by the Shenzhen Stock Exchange [1]

Group 1 - The company Renhe Pharmaceutical announced the resignation of Mr. Chen Guofeng as the Secretary of the Board due to personal reasons, and he will no longer hold any position within the company after his resignation [1] - Following the resignation, the Board of Directors approved the appointment of Mr. Jiang Feng as the new Secretary of the Board, with a term aligned with the current Board's tenure [1]

为保证董事会工作的正常进行，根据《公司法》等相关法律法规和《公司章 程》的规定，经公司董事长提名，董事会提名委员会任职资格审查，公司第十届 董事会第六次临时会议审议通过了《关于聘任姜锋先生为董事会秘书的议案》， 同意聘任姜锋先生为公司董事会秘书，任期与公司第十届董事会任期相同。姜锋 先生已取得深圳证券交易所颁发的《董事会秘书资格证书》，具备履行职责所必 须的专业知识能力。 仁和药业股份有限公司 关于公司董秘辞职及聘任董秘的公告 公司董事会秘书姜锋先生的联系方式如下： 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会秘书办公电话：0791-83896755 办公传真：0791-83896755 仁和药业股份有限公司（以下简称"公司"）董事会近日收到公司董事会秘 书陈国锋先生的书面辞职报告，陈国锋先生因个人原因，申请辞去公司董事会秘 书职务。根据相关法律法规、规范性文件的有关规定，陈国锋先生的辞职报告自 送达董事会时生效。陈国锋先生原任期于 2028 年 5 月 26 日到期，未持有公司股 份，辞职后将不再担任公司任何职务。 电子邮箱：rh000650@12 ...

证券代码：000650 证券简称：仁和药业 公告编号：2026-001 仁和药业股份有限公司 第十届董事会第六次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 仁和药业股份有限公司第十届董事会第六次临时会议通知于 2026 年 2 月 6 日以送达、电子邮件等方式发出，会议于 2026 年 2 月 9 日以通讯方式在南昌元 创国际 18 层公司会议室召开。会议应到董事 9 人，实到董事 9 人。董事长杨潇 先生主持本次会议，会议符合《公司法》和《公司章程》的有关规定。经与会董 事认真审议，会议审议通过了《关于聘任姜锋先生为董事会秘书的议案》。 二〇二六年二月九日 1 董事会秘书的提名已经深圳证券交易所审核无异议，公司第十届独立董事专 门会议事前审核并同意董事会聘任姜锋先生为董事会秘书。 董事会秘书办公电话：0791-83896755 办公传真：0791-83896755 电子邮箱：rh000650@126.com 地 址：江西省南昌市红谷滩区红谷中大道 998 号绿地中央广 场 B 区元创国际 18 层（330038） 此议案表决结果：同意票 ...

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced the resignation of its board secretary, Chen Guofeng, due to personal reasons, effective immediately upon delivery of his resignation report to the board [1] Group 1: Resignation Details - Chen Guofeng's original term was set to expire on May 26, 2028, and he did not hold any shares in the company [1] - Following his resignation, Chen Guofeng will no longer hold any position within the company [1] Group 2: Appointment of New Secretary - To ensure the normal operation of the board, the company chairman nominated Jiang Feng as the new board secretary [1] - The appointment was approved during the sixth temporary meeting of the tenth board, with Jiang Feng's term aligning with that of the current board [1] - Jiang Feng possesses the necessary professional knowledge and skills, having obtained the Board Secretary Qualification Certificate issued by the Shenzhen Stock Exchange [1]